目的 回顾分析我医院近8年混合痔行Milligan-Morgan术式治疗的患者的临床病历资料,探索术后出现胃肠道症状的危险因素。方法 选取我医院2012年1月—2019年6年期间行Milligan-Morgan术式治疗的混合痔患者1 221例,分成术后胃肠道症状组和未出现胃肠道症状组,比较两组间的差异,分析其相关危险因素。结果 1 221例混合痔患者中出现胃肠道症状的为168例,发生率为13.8%(168/1 221);单因素分析结果显示,高血压、全麻麻醉方式是术后出现胃肠道症状的相关因素,差异有统计学意义;多因素Logistic回归分析结果显示,高血压、全麻麻醉方式是术后出现胃肠道症状的独立危险因素。结论 混合痔患者行Milligan-Morgan术式治疗出现胃肠道症状率较高;围手术期控制患者血压,以及慎重选择全麻麻醉方式可能有效减少胃肠道症状发生率。

Objective To explored the risk factors of gastrointestinal symptoms after operation by retrospectively analyzing the clinical records of patients with mixed hemorrhoids treated by Milligan-Morgan operation in our hospital in recent 8 years. Methods 1 221 patients with mixed hemorrhoids treated by Milligan-Morgan operation in our hospital from January 2012 to June 2016 were divided into two groups: the group with digestive tract symptoms after operation and the group without digestive tract symptoms. The differences between the two groups were compared and the related risk factors were analyzed. Results Among 1 221 patients with mixed hemorrhoids, 168 had gastrointestinal symptoms, whose incidence was 13.8%(168/1 221). Univariate analysis showed that hypertension and general anesthesia were the related factors of gastrointestinal symptoms after operation, and the difference was statistically significant. Multivariate logistic regression analysis showed that hypertension and general anesthesia were the independent risk factors. Conclusion Milligan-Morgan operation for mixed hemorrhoids has a high incidence of digestive tract symptoms. Perioperative blood pressure control and careful selection of general anesthesia may effectively reduce the incidence of digestive tract symptoms.

目的 回顾分析我医院近9年产妇行剖宫产术治疗的患者的住院病历资料,探索术后出现切口脂肪液化的危险因素。方法 选取我医院2011年1月—2019年8月期间行剖宫产术治疗的产妇患者1 018例,分成术后切口脂肪液化组和甲级愈合组,比较2组间的差异,分析其相关危险因素。结果 1 018例产妇患者中出现切口脂肪液化的为34例,发生率为3.34%(34/1 018);单因素分析结果显示,糖尿病、体质指数超重、7 cm以上切口长度是术后出现切口脂肪液化的相关因素,差异有统计学意义;多因素Logistic回归分析结果显示,糖尿病、体质指数超重、7 cm以上切口长度是术后出现切口脂肪液化的独立危险因素。结论 产妇患者行剖宫产术治疗出现切口脂肪液化率较高;围手术期控制患者血糖,以及孕期控制体质指数、缩小剖宫产手术切口长度可能有效地减少切口脂肪液化发生率。

Objective To retrospectively analyze the medical records of patients undergoing cesarean section in our hospital in recent 9 years, and explore the risk factors of incision fat liquefaction after operation. Methods 1 018 patients undergoing cesarean section in our hospital from January 2011 to August 2019 were divided into two groups: incision fat liquefaction group and grade A healing group. The differences between the two groups were compared and the risk factors were analyzed. Results Among 1 018 parturients, 34 had incision fat liquefaction, and the incidence was 3.34% (34/1018). Univariate analysis showed that diabetes mellitus, overweight body mass index and incision length of more than 7 cm were risk factors for incision fat liquefaction after operation, and the difference was statistically significant. Multivariate logistic regression analysis showed that diabetes mellitus, overweight body mass index and incision length over 7 cm were independent risk factors for incision fat liquefaction. Conclusion The incision fat liquefaction rate is higher in patients undergoing cesarean section. Controlling blood sugar level, body mass index during pregnancy and shortening the length of incision during perioperative period may effectively reduce the incidence of incision fat liquefaction.

目的 探讨二氢丹参酮Ⅰ在胃癌细胞中的抗癌作用。方法 采用 3-(4,5-二甲基噻唑-2)-2,5-二苯基四氮唑溴盐法(MTT法)测定细胞活力。流式细胞术检测细胞内活性氧(ROS)水平。荧光法测定Caspase活性。裸鼠胃癌模型验证DHTS的抗癌活性。结果 MTT实验结果表明,DHTS对HCG27和AGS细胞活力具有明显的剂量依赖性和时间依赖性。在DHTS处理的HCG27和AGS细胞中,细胞内ROS水平升高,凋亡细胞增多。 在DHTS处理的HCG27和AGS细胞中发现caspase-3和caspase-8活性增高,caspase-9活性不变。用N -乙酰半胱氨酸阻断ROS生成可显著逆转DHTS诱导的细胞凋亡。DHTS显著抑制小鼠肿瘤瘤体体积的增加。结论 所有的研究结果都有力的说明,DHTS可以在HCG27和AGS人胃癌细胞中启动活性氧生成,诱导氧化应激和细胞凋亡,值得作为抗癌药物进一步开发。

Objective To evaluate the anticancer actions of dihydrotanshinone Ⅰ(DHTS)in gastric cancer cells. Methods Cell viability was determined using 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)assay. Intracellular reactive oxygen species (ROS)levels were determined using flow cytometry. Caspase activities were measured with fluorometric assay. The anticancer activity of DHTS in nude mouse gastric cancer model was verified. Results MTT assay showed that DHTS greatly inhibited HCG27 or AGS cell viability in dose- and time-dependent manners. Elevated intracellular ROS levels and increased apoptotic cells were observed in DHTS-treated HCG27 or AGS cells. In addition, activation of caspase-3 and caspase-8, rather than caspase-9, were noticed in DHTS-treated HCG27 or AGS cells. Furthermore, blocking ROS generation with N-acetylcysteine markedly reversed DHTS-induced cell apoptosis. DHTS inhibited the increase of tumor volume in mice. Conclusion All the findings strongly suggest that DHTS may initiate ROS generation and induce oxidative stress and cell apoptosis in HCG27 or AGS human gastric cancer cells, which deserves to be further developed as an anticancer agent.